<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97490">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958957</url>
  </required_header>
  <id_info>
    <org_study_id>201311BDY04V05</org_study_id>
    <nct_id>NCT01958957</nct_id>
  </id_info>
  <brief_title>A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.</brief_title>
  <official_title>A Multicenter Safety Clinical Trial of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke With Syndrome of Intermingled Phlegm and Blood Stasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Kanion Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Bionovo Medicine Development Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu Kanion Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the
      treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ginkgolides Meglumine Injection was jointly developed by China Pharmaceutical University and
      Jiangsu Kanion Pharmaceutical Co., Ltd. Its pharmacal ingredients are ginkgo lactones ,
      ginkgo lactone B, ginkgo lactone K, etc; Excipients for meglumine, citric acid, sodium
      chloride. It is used to treat stroke (mild-to-moderate cerebral infarction) in recovery
      phlegm and Syndrome of Intermingled Phlegm and Blood Stasis.

      The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the
      treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>vital signs after 10 minutes of stasis.</measure>
    <time_frame>0，14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood routine tests</measure>
    <time_frame>0, 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>0, 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient- reported outcomes,PRO</measure>
    <time_frame>0, 14 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver function tests</measure>
    <time_frame>0, 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney function tests</measure>
    <time_frame>0, 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urine routine tests</measure>
    <time_frame>0, 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stool routine +occult blood tests</measure>
    <time_frame>0, 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coagulation function tests</measure>
    <time_frame>0, 14 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>NIH Stroke Scale，NIHSS</measure>
    <time_frame>baseline</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6000</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Ginkgolides Meglumine Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous drip slowly. A 1 (25 mg), will be taken slowly into the 0.9% sodium chloride injection diluted in 250 ml before use, then slow intravenous drip, once a day. The dripping speed must be strictly controlled. For the first time when using, dripping speed should be controlled for 10 ~ 15 drops per minute. After 30 minutes treatment without discomfort, dripping speed can be appropriately increased, but no more than 30 drops per minute.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ginkgolides Meglumine Injection</intervention_name>
    <description>25mg, intravenous drip, once a day. Number of Cycles: 14 days.</description>
    <arm_group_label>Ginkgolides Meglumine Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients according to diagnostic standards on western medical ischemic stroke;

          -  patients according to diagnostic standards on Chinese medical attack to meridians;

          -  patients according to differentiation standards on syndrome of intermingled phlegm
             and blood stasis;

          -  2 weeks to 6 months after attack;

          -  Age between 18-80 years;

          -  patients must volunteer to participate in this study and sign the informed consent
             form.

        Exclusion Criteria:

          -  patients accompanying unconsciousness or severe dementia;

          -  ALT, AST≥2 times of upper limit of normal;

          -  patients with other severe diseases such as disease in circulatory system,
             hematopoietic system, digestive system, endocrine system etc;

          -  patients allergic to Ginkgo biloba drugs，Meglumine and meglumine agents;

          -  patients who are pregnant, lactating or planning for pregnancy;

          -  patients with insanity;

          -  patients who are not suitable for clinical trial under doctors' consideration;

          -  patients with Merge bleeding after infarction or patients with hemorrhagic tendency;

          -  patients with lower extremity venous thrombosis;

          -  patients who have participated in other clinical trial within 1 month.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gao Ying, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongzhimen Hospital, Beijing</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhou Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongzhimen Hospital, Beijing</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CN027</name>
      <address>
        <city>Baotou</city>
        <zip>014016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN001</name>
      <address>
        <city>Beijing</city>
        <zip>100007</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhou Li, Docotor</last_name>
      <phone>86-13693293363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN041</name>
      <address>
        <city>Changchun</city>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao Jianjun</last_name>
      <phone>15948000771</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN043</name>
      <address>
        <city>Changchun</city>
        <zip>130022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN029</name>
      <address>
        <city>Changzhi</city>
        <zip>046011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN039</name>
      <address>
        <city>Chengdu</city>
        <zip>610072</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Qian</last_name>
      <phone>18981838959</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN007</name>
      <address>
        <city>Dalian</city>
        <zip>116021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN042</name>
      <address>
        <city>Dalian</city>
        <zip>116033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN044</name>
      <address>
        <city>Daqing</city>
        <zip>163000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN018</name>
      <address>
        <city>Daqing</city>
        <zip>163001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN045</name>
      <address>
        <city>Ha'erbin</city>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN046</name>
      <address>
        <city>Ha'erbin</city>
        <zip>150076</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN036</name>
      <address>
        <city>Hefei</city>
        <zip>230061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mu Yanfang</last_name>
      <phone>13956997899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN035</name>
      <address>
        <city>Hefei</city>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Kai</last_name>
      <phone>13805512494</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN024</name>
      <address>
        <city>Hegang</city>
        <zip>154100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN025</name>
      <address>
        <city>Hegang</city>
        <zip>154100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN002</name>
      <address>
        <city>Hengyang</city>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xie Ming</last_name>
      <phone>86-13973402513</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN026</name>
      <address>
        <city>Huhehaote</city>
        <zip>010010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhu Runxiu</last_name>
      <phone>18604713193</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN022</name>
      <address>
        <city>Jilin</city>
        <zip>132011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Wei</last_name>
      <phone>86-13904401535</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN030</name>
      <address>
        <city>Jinan</city>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN021</name>
      <address>
        <city>Jingdezhen</city>
        <zip>333003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Le Zhiqing</last_name>
      <phone>86-13879883627</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN014</name>
      <address>
        <city>Kaifeng</city>
        <zip>475099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN013</name>
      <address>
        <city>Luohe</city>
        <zip>462099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN003</name>
      <address>
        <city>Nanjing</city>
        <zip>210005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xu Tianshu</last_name>
      <phone>86-13701479808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN040</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>CN006</name>
      <address>
        <city>Shenyang</city>
        <zip>110034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN008</name>
      <address>
        <city>Shenyang</city>
        <zip>110032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN017</name>
      <address>
        <city>Shenyang</city>
        <zip>110091</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN005</name>
      <address>
        <city>Shenzhen</city>
        <zip>518034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wu Jun</last_name>
      <phone>86-13510331566</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN023</name>
      <address>
        <city>Siping</city>
        <zip>136099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN016</name>
      <address>
        <city>Suihua</city>
        <zip>151100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN028</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Jie</last_name>
      <phone>86-13503513919</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN037</name>
      <address>
        <city>Taiyuan</city>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hou Yuli</last_name>
      <phone>13327432369</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN019</name>
      <address>
        <city>Tangshan</city>
        <zip>063003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang Xiumin</last_name>
      <phone>86-13103050167</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN020</name>
      <address>
        <city>Tangshan</city>
        <zip>063001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Ruying</last_name>
      <phone>86-13333299773</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN033</name>
      <address>
        <city>Tianjin</city>
        <zip>300192</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dai Xiaoyu</last_name>
      <phone>13012289781</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN034</name>
      <address>
        <city>Tianjin</city>
        <zip>300100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang Heng</last_name>
      <phone>13682050928</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN032</name>
      <address>
        <city>Wuhan</city>
        <zip>430080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chen Hangying</last_name>
      <phone>13554025815</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN012</name>
      <address>
        <city>Xi'an</city>
        <zip>710001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN010</name>
      <address>
        <city>Xi'an</city>
        <zip>710054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN031</name>
      <address>
        <city>Xianning</city>
        <zip>437099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN011</name>
      <address>
        <city>Xianyang</city>
        <zip>712021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN009</name>
      <address>
        <city>Xianyang</city>
        <zip>712099</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>CN004</name>
      <address>
        <city>Yancheng</city>
        <zip>224001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao Dongpo</last_name>
      <phone>86-13770179899</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN038</name>
      <address>
        <city>Yuncheng</city>
        <zip>044000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Kedong</last_name>
      <phone>18935096751</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>CN015</name>
      <address>
        <city>Zhumadian</city>
        <zip>463000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>November 24, 2013</lastchanged_date>
  <firstreceived_date>September 29, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ischemic stroke</keyword>
  <keyword>safety</keyword>
  <keyword>Ginkgolides Meglumine Injection</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
